Foundation Medicine announced the launch of its FoundationOne RNA, a tissue-based RNA sequencing test. The test is claimed to be capable of detecting cancer-related fusions across 318 genes, reporting fusions present in non-small cell lung cancer, cholangiocarcinoma, sarcoma, and pancreatic, thyroid, and bladder cancer. The test was first made available in September 2023 for research and investigational use and is now being launched for clinical use.
The company asserts that the FoundationOneRNA can provide an additional layer of fusion detection in 318 genes, expanding its capabilities beyond its DNA sequencing test, FoundationOne CDx. The RNA test results are combined with those of FoundationOne CDx into a single report to deliver actionable fusion data to healthcare providers.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.